Long‑term treatment response in myelodysplastic syndrome 5q minus after discontinuation of lenalidomide – a case report
MUDr. Petra Bělohlávková, Ph.D.
IV. interní hematologická klinika LF UK a FN Hradec Králové
MDS 5q minus syndrome belongs to the category of low-risk MDS with a good prognosis. Lenalidomide treatment can effectively lead to transfusion independence and cytogenetic remission with improved the overall survival. We present a case of a patient in whom long-term remission of the disease lasts 5,5 years after discontinuation of treatment by lenalidomide.
del(5q), myelodysplastic syndromes, lenalidomide
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...